Multiple Sclerosis Ms clinical trials

Explore recruiting multiple sclerosis ms clinical trials.

Recruiting multiple sclerosis ms studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Multiple Sclerosis Ms trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multicenter, Double Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis

Spain, Poland, Portugal, Italy, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

Croatia, Czechia

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Single Arm, Open Label Multicentre Extension Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial

Hungary, Norway, Croatia, Denmark, Slovakia, Belgium +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis

Belgium, France, Czechia, Spain, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

AMANTADINE AND TRANSCRANIAL MAGNETIC TRANSCRANIAL MAGNETIC STIMULATION FOR FATIGUE IN MULTIPLE SCLEROSIS: A PHASE III, CONTROLLED, RANDOMISED, DOUBLE-BLIND, CROSSOVER TRIAL

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis

Finland, Netherlands, Spain, Poland, Slovakia, Bulgaria +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multiple Sclerosis Ms trials by city

Multiple Sclerosis Ms in Toronto Multiple Sclerosis Ms in Vancouver Multiple Sclerosis Ms in Montreal Multiple Sclerosis Ms in Calgary Multiple Sclerosis Ms in Edmonton Multiple Sclerosis Ms in Ottawa Multiple Sclerosis Ms in Winnipeg Multiple Sclerosis Ms in Quebec City Multiple Sclerosis Ms in Hamilton Multiple Sclerosis Ms in Kitchener Multiple Sclerosis Ms in London Multiple Sclerosis Ms in Halifax Multiple Sclerosis Ms in New York Multiple Sclerosis Ms in Los Angeles Multiple Sclerosis Ms in Chicago Multiple Sclerosis Ms in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease